Ryan J. Watts - 13 Feb 2024 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
13 Feb 2024
Transactions value $
-$165,794
Form type
4
Filing time
15 Feb 2024, 21:15:20 UTC
Previous filing
11 Jan 2024
Next filing
29 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$165,793 -9,589 -3.87% $17.29 238,067 13 Feb 2024 Direct F1, F2, F3, F4
holding DNLI Common Stock 2,242,604 13 Feb 2024 See footnote F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price
F3 Includes 202,200 RSUs.
F4 Reflects 25,759 shares previously disclosed as held indirectly; but have been determined to be held directly.
F5 The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.